Nuvalent Targets FDA Approval for Zidesamtinib by September 2026
Event summary
- FDA assigned a PDUFA target action date of September 18, 2026 for zidesamtinib in TKI pre-treated ROS1-positive NSCLC.
- Nuvalent plans to submit NDA for neladalkib in TKI pre-treated ALK-positive NSCLC in H1 2026.
- Company raised $500M in public offering in November 2025, extending runway into 2029.
- Net loss for 2025 was $425.4M, with R&D expenses at $307M.
The big picture
Nuvalent is advancing toward its first potential FDA approval with zidesamtinib, positioning itself as a key player in precision oncology. The company's strong financial position and ongoing clinical trials for multiple candidates highlight its strategic focus on addressing unmet needs in ROS1-positive, ALK-positive, and HER2-altered NSCLC. The $500M raise in 2025 provides significant runway to execute its OnTarget 2026 operating plan.
What we're watching
- Regulatory Timing
- Whether Nuvalent can secure FDA approval for zidesamtinib by the September 2026 PDUFA date.
- Commercial Readiness
- The pace at which Nuvalent can establish commercial infrastructure for potential 2026 launches.
- Pipeline Expansion
- How Nuvalent's label expansion efforts for TKI-naïve patients will impact market positioning.
Related topics